Return on Capital Employed Overview: Amedisys

After pulling data from Benzinga Pro it seems like during Q2, Amedisys AMED earned $78.14 million, a 13.49% increase from the preceding quarter. Amedisys also posted a total of $564.17 million in sales, a 5.03% increase since Q1. Amedisys earned $68.85 million, and sales totaled $537.14 million in Q1.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Amedisys's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Amedisys posted an ROCE of 0.09%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Amedisys's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Upcoming Earnings Estimate

Amedisys reported Q2 earnings per share at $1.69/share, which beat analyst predictions of $1.67/share.